Journal of Public Health Policy

, Volume 35, Issue 2, pp 137–161

A quiet revolution in global public health: The World Health Organization’s Prequalification of Medicines Programme

  • Ellen F M ‘t Hoen
  • Hans V Hogerzeil
  • Jonathan D Quick
  • Hiiti B Sillo
Original Article


Problems with the quality of medicines abound in countries where regulatory and legal oversight are weak, where medicines are unaffordable to most, and where the official supply often fails to reach patients. Quality is important to ensure effective treatment, to maintain patient and health-care worker confidence in treatment, and to prevent the development of resistance. In 2001, the WHO established the Prequalification of Medicines Programme in response to the need to select good-quality medicines for UN procurement. Member States of the WHO had requested its assistance in assessing the quality of low-cost generic medicines that were becoming increasingly available especially in treatments for HIV/AIDS. From a public health perspective, WHO PQP’s greatest achievement is improved quality of life-saving medicines used today by millions of people in developing countries. Prequalification has made it possible to believe that everyone in the world will have access to safe, effective, and affordable medicines. Yet despite its track record and recognized importance to health, funding for the programme remains uncertain.


medicines quality HIV WHO Prequalification of medicines programme access to medicines patents 

Notes and References

  1. World Health Organization (WHO). (1987) The Rational Use of Drugs: Report of the Conference of Experts Nairobi, 26–29 November, 1985.Google Scholar
  2. World Health Organization (WHO). (2011) Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union., accessed 18 November 2013.
  3. World Health Organization (WHO). (2013) WHO List of Prequalified Medicinal Products., accessed 18 November 2013.
  4. UNAIDS. (2012) World AIDS Day Report 2012. Geneva.Google Scholar
  5. Gellman, B. (2000) An unequal calculus of life and death; as millions perished in pandemic, firms debated access to drugs; players in the debate over drug availability and pricing. The Washington Post. 27 December, p. A01.Google Scholar
  6. ‘t Hoen, E., Berger, J., Calmy, A. and Moon, S. (2011) Driving a decade of change: HIV/AIDS, patents and access to medicines for all. Journal of the International AIDS Society. 14:2–12.Google Scholar
  7. World Trade Organization (WTO). (2007) The results of the Uruguay round of multilateral trade negotiations. Geneva,, accessed 18 November 2013.
  8. McNeil Jr, D. (2002) New List of Safe AIDS Drugs. The New York Times. 20 March,, accessed 18 November 2013.
  9. Connor, J., Rafter, N. and Rodgers, A. (2004) Do Fixed-Dose Combination Pills Or Unit-of-use Packaging Improve Adherence? A Systematic Review. Bulletin of the World Health Organization. 82:935-9,, accessed 18 November 2013.
  10. Laurent, C. et al ANRS 1274 study group (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. The Lancet 364 (9428): 29–34.CrossRefGoogle Scholar
  11. GlaxoSmithKline (GSK) offered a combination of abacavir, lamivudine and zidovudine in one pill in early 2000.Google Scholar
  12. Bate, R. (2005) Slippery AIDS Statistics. American Enterprise Institute. AEI Online,, accessed 18 November 2013.
  13. Adelman, C. and Norris, J. (2004) Fighting AIDS on the Cheap. Hudson Institute,, accessed 18 November 2013.Google Scholar
  14. (2004) Generics for AIDS (Editorial). Nature Immunology 5:1089.Google Scholar
  15. Brown, D. (2004) Bush’s AIDS Program Balks at Foreign Generics US Insistence on More Tests Complicates Rollout.? The Washington Post, 27 March, p. A03.Google Scholar
  16. Dyer, O (2004) Bush accused of blocking access to cheap AIDS drugs. British Medical Journal 328:783.1.Google Scholar
  17. Act Up. (2004) Global AUDS Coordinator Tobias Defends US Policy Not to Use Generic Fixed-Dose Combination Antoretroviral Drugs, 29 April,, accessed 18 November 2013.
  18. ‘t Hoen, E. (2004) Generic drugs for fighting AIDS. The New York Times Opinion, 2 April,, accessed 18 November 2013.
  19. Rägo, L. (2004) How WHO ensures the quality of antiretrovirals and other essential medicines, 7 September,, accessed 18 November 2013.
  20. World Health Organization (WHO). (2004) Scientific and technical principles for fixed dose combination products. Botswana: WHO, 22 April.Google Scholar
  21. 379 organisations. (2004) Letter to Ambassador Randall Tobias. Re: Generic medicines and US-initiatied conference on Fixed-Dose Combinations, 29 March,, accessed 18 November 2013.
  22. Brown, S. and Lee, B. (2004) Letter to Ambassador Randall Tobias, 24 March,, accessed 18 November 2013.
  23. United States General Accounting Office. (2004) Report to the Chairman, Subcommittee on Foreign Operations, Export Financing, and Related Programs, Committee on Appropriations, House of Representatives. GLOBAL HEALTH, USAIDS Coordinator Addressing Some Key Challenges to Expanding Treatment, but Others Remain. GOA-04-784,, accessed 18 November 2013.
  24. Kapstein, E.B. and Busby, J.W. (2013) AIDS Drugs for All: Social Movements and Market Transformation. Cambridge, UK: Cambridge University Press, p. 207.CrossRefGoogle Scholar
  25. World Health Assembly Resolution: WHA/50 2004.Google Scholar
  26. Médecins Sans Frontières (MSF). (2004) Briefing note: Two Cipla AIDS Drugs Removed from WHO Prequalification List, 16 June,, accessed 18 November 2013.
  27. (2004) The important world of drug prequalification. The Lancet 364(9448):1830.Google Scholar
  28. Van Zyl, A.J. (2011) Ensuring the quality of medicines – A decade of prequalification. WHO Drug Information 25: 231–239.Google Scholar
  29. World Health Organization (WHO). (2013) Prequalification of active pharmaceutical ingredients. WHO Drug Information 26(3): 255–260.Google Scholar
  30. World Health Organization (WHO). (2011) The WHO prequalification programme and the Medicines Patent Pool: A Primer,, accessed 18 November 2013.
  31. World Health Organization (WHO). (2009) WHO medicines prequalification: progress in 2008. WHO Drug Information 23(1): 3–7.Google Scholar
  32. World Health Organization (WHO). (2011) Who prequalification of medicines programme (Pqp) facts and figures for 2011,, accessed 18 November 2013.
  33. World Health Organization (WHO). (2013) WHO model Lists of Essential Medicines,, accessed 18 November 2013.
  34. Kaplan, W. and Laing, R. (2004) Priority Medicines for Europe and the World. World Health Organization Department of Essential Drugs and Medicines Policy,, accessed 18 November 2013.
  35. Kaplan, W., Wirtz, V.J., Mantel-Teeuwisse, A., Stolk, P., Duthey, B. and Laing, R. (2013) Priority Medicines for Europe and the World – 2013 Update. World Health Organization,, accessed 18 November 2013.
  36. WHO/HTP/PSM/QSM (2005). A Business Plan for the Prequalification Program 2006–2007. 1 September.Google Scholar
  37. USAID, SCMC, PEPFAR. (2012) Six years of saving lives through stronger public health supply chains,, accessed 18 November 2013.
  38. UNITAID. (2013) UNITAID Strategy 2013–2016,, accessed 18 November 2013.
  39. World Health Organization (WHO). (2013) 15 facts on HOV treatment scale-up and new WHO ARV guidelines 2013,, accessed 15 November 2013.
  40. World Health Organization (WHO). (2010) Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries. Geneva,, accessed 18 November 2013.
  41. United States Government Accountability Office. (2013) President’s Emergency Plan for AIDS relief. Drug Supply Chains Are Stronger, but More Steps are Needed to Reduce Risks. GAO-13-483,, accessed 18 November 2013.
  42. US Food and Drug Administration (USFDA). (2004) Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan,, accessed 18 November 2013.
  43. Waning, B. et al (2010) Intervening in global markets to improve access to HIV/AIDS treatment: An analysis of international policies and the dynamics of global antiretroviral medicines markets. Globalization and Health 14 (1): 9.CrossRefGoogle Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Ltd 2014

Authors and Affiliations

  • Ellen F M ‘t Hoen
    • 1
  • Hans V Hogerzeil
    • 2
  • Jonathan D Quick
    • 3
  • Hiiti B Sillo
    • 4
  1. 1.Independent Consultant, Medicines Law and PolicyParisFrance
  2. 2.University of Groningen9713 AV GroningenThe Netherlands
  3. 3.Management Sciences for HealthCambridgeUSA
  4. 4.Tanzania Food and Drugs Authority (TFDA)Dar es SalaamTanzania

Personalised recommendations